Regeneron Pharmaceuticals Inc. (REGN) Stock Price Down 1.3%
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 1.3% on Friday . The company traded as low as $387.63 and last traded at $388.19, with a volume of 389,422 shares. The stock had previously closed at $393.40.
A number of analysts recently weighed in on the stock. Piper Jaffray Cos. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Sunday, May 8th. Leerink Swann set a $511.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, August 6th. RBC Capital Markets reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, August 6th. Cowen and Company reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, June 6th. Finally, Robert W. Baird reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, May 16th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $470.73.
The company has a market cap of $40.66 billion and a price-to-earnings ratio of 60.63. The company has a 50-day moving average of $408.55 and a 200-day moving average of $389.38.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.17. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.24 billion. The company’s revenue was up 21.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.89 EPS. Equities research analysts expect that Regeneron Pharmaceuticals Inc. will post $10.93 earnings per share for the current year.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction on Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the sale, the director now owns 15,125 shares of the company’s stock, valued at $6,428,125. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Sanofi bought 64,731 shares of the stock in a transaction on Tuesday, June 14th. The stock was purchased at an average cost of $363.86 per share, for a total transaction of $23,553,021.66. The disclosure for this purchase can be found here.
A hedge fund recently raised its stake in Regeneron Pharmaceuticals stock. Schwab Charles Investment Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 16.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 218,216 shares of the biopharmaceutical company’s stock after buying an additional 31,441 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.21% of Regeneron Pharmaceuticals worth $118,463,000 as of its most recent SEC filing.
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.